I can't speak to the physician side. I'm sure they have notional benchmarks that allow them to assess, at least in the safe confines of their own minds.
In terms of the statistician on the committee, it would be a horrible case of bias.
I'm not touting abilities, but majoring in math in college we had an ethics class (that I slept through), and I think I remember something about cross studies influencing analysis. And, not in all cases, but this case I'd argue fell within this borderline.
The statistician has to know that the nuances of the science change meanings within the figures: if looking at OS, a drug with less antigens gives the same OS as another with more antigens then there's a conflict. An apples and oranges thing. In an analysis he wouldn't be able to say, "Well, this has the same OS as drug Beta." It would be unprofessional. He just needs to say, "OS is X. PFS is Y." etc.
So, yes and no.
It can only help if no other medicine can do what DCVax can do (in a good way).
News 
Market Data 
Discover 
